4
Changes in Ownership
BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-073003
Chief Commercial Officer sold 244 shares at $1.26 ($308)
- Chief Commercial Officer acquired 750 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Wiley Matthew T. Chief Commercial Officer | 2024-06-15 | Option exercise 10b5-1 | +750 | 3,742 | D | ||
| Wiley Matthew T. Chief Commercial Officer | 2024-06-17 | Sale 10b5-1 | −244 | $1.26 | $308 | 3,498 | D |
| Derivatives | |||||||
| Wiley Matthew T. Chief Commercial Officer | 2024-06-15 | Option exercise · Restricted Stock Units 10b5-1 | +750 | 8,250 | D | ||
| Open-market sales · 244 sh · avg $1.26 · $308 | |||||||
Loading xslF345X05/tm2417544-6_4seq1.xml…